Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

Items 101–200 of 764

Li–Fraumeni syndrome heterogeneity
Gargallo, P., Yáñez, Y., Segura, V., Juan, A., Torres, B., Balaguer, J., Oltra, S., Castel, V., & Cañete, A. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02236-2 · Cited by 41
The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53
Menéndez, D., Nguyen, T., Snipe, J. R., & Resnick, M. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0019 · Cited by 43
Molecular landscape of Hereditary Melanoma
Arnaut, J. R. M. B., Guimarães, I. D. S., dos Santos, A. C. E., da Silva, F. D. M. L., Machado, J. R. D. S., & de Melo, A. C. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103425 · Cited by 41
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens
Evans, D. G., Lalloo, F. I., Howell, S. J., Verhoef, S., Woodward, E. R., & Howell, A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3697-z · Cited by 39
A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next‐generation sequencing hereditary pan‐cancer panel are acquired somatically
Coffee, B. W., Cox, H. C., Bernhisel, R., Manley, S., Bowles, K. R., Roa, B. B., & Mancini‐DiNardo, D. (2019) · Human Mutation · doi:10.1002/humu.23910 · Cited by 41
Malignant Phyllodes Tumor of the Breast: A Practice Review
Fêde, Â., Souza, R. P., Doi, M., Brot, M. D., Osório, C. A. B. D. T., Gondim, G. R. M., da Rocha, J. C. C., Jbili, R., Bitencourt, A. G. V., de Souza, J. A., et al. (2021) · Clinics and Practice · doi:10.3390/clinpract11020030 · Cited by 38
Should Genetic Testing be Offered for Children? The Perspectives of Adolescents and Emerging Adults in Families with Li‐Fraumeni Syndrome
Alderfer, M. A., Lindell, R. B., Viadro, C. I., Zelley, K., Valdez, J. M., Mandrell, B. N., Ford, C. A., & Nichols, K. E. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0091-x · Cited by 38
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels
Feliubadaló, L., López‐Fernández, A., Pineda, M., Dı́ez, O., Valle, J. D., Gutiérrez‐Enríquez, S., Teulé, À., González, S., Stjepanovic, N., Salinas, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32304 · Cited by 38
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum
Caron, O., Frébourg, T., Benusiglio, P. R., Foulon, S., & Brugières, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1358 · Cited by 37
Self-citation
HACE1 is a potential tumor suppressor in osteosarcoma
El-Naggar, A. M., Clarkson, P. W., Negri, G. L., Turgu, B., Zhang, F., Anglesio, M. S., & Sorensen, P. H. B. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1276-4 · Cited by 37
Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts
Shin, S. J., Dodd-Eaton, E. B., Peng, G., Bojadzieva, J., Chen, J., Amos, C. I., Frone, M. N., Khincha, P. P., Mai, P. L., Savage, S. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0728 · Cited by 37
Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors
Mastellaro, M. J., Seidinger, A. L., Kang, G., Abrahão, R., MIRANDA, E. C. M., Pounds, S. B., Cardinalli, I. A., Aguiar, S. S., de Figueiredo, B. C., Galindo, C. R., et al. (2017) · Cancer · doi:10.1002/cncr.30703 · Cited by 36
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation
Ferreira, A. M., Balderrama-Brondani, V., Helena, V. P., Charchar, H. L. S., Zerbini, M. C. N., Leite, L. A. S., Hoff, A. O., Latronico, A. C., Mendonca, B. B., Estevez-Diz, M. D. P., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.011 · Cited by 36
Germline TP53 Testing in Breast Cancers: Why, When and How?
Evans, D. G., Woodward, E. R., Bajalica‐Lagercrantz, S., Oliveíra, C., & Frébourg, T. (2020) · Cancers · doi:10.3390/cancers12123762 · Cited by 39
Breast Cancer Risk Assessment Models and High-Risk Screening
Barke, L. D., & Freivogel, M. E. (2017) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2016.12.013 · Cited by 36
New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients
Djursby, M., Madsen, M. B., Frederiksen, J. H., Berchtold, L. A., Therkildsen, C., Willemoe, G. L., Hasselby, J. P., Wikman, F. P., Okkels, H., Skytte, A., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.566266 · Cited by 35
The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.
Miller, M., Shirole, N. H., Tian, R., Pal, D., & Sordella, R. (2016) · PubMed · Cited by 35
Screening with whole‐body magnetic resonance imaging in pediatric subjects with Li–Fraumeni syndrome: A single institution pilot study
O'Neill, A. F., Voss, S. D., Jagannathan, J. P., Kamihara, J., Nibecker, C., Itriago‐Araujo, E., Masciari, S., Parker, E., Barreto, M., London, W. B., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26822 · Cited by 34
One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene
Fostira, F., Konstantopoulou, I., Apostolou, P., Papamentzelopoulou, M., PAPADIMITRIOU, C. A., Faliakou, E. C., Christodoulou, C., Boukovinas, I., Razis, E. D., Tryfonopoulos, D. J., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106189 · Cited by 34
Cancer-related Mutations with Local or Long-range Effects on an Allosteric Loop of p53
Degn, K., Beltrame, L., Hede, F. D., Sora, V., Nicolaci, V., Vabistsevits, M., Schmiegelow, K., Wadt, K., Tiberti, M., Lambrughi, M., et al. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167663 · Cited by 28
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry
Penkert, J., Strüwe, F. J., Dutzmann, C. M., Dörgeloh, B. B., Montellier, E., Freyçon, C., Keymling, M., Schlemmer, H., Sänger, B., Hoffmann, B., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01332-1 · Cited by 32
Rate of Pathogenic Germline Variants in Patients With Lung Cancer
Sorscher, S. M., LoPiccolo, J., Heald, B., Chen, E. Y., Bristow, S. L., Michalski, S. T., Nielsen, S. M., Lacoste, A. M. B., Keyder, E., Lee, H., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00190 · Cited by 33
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)
Bancroft, E. K., Saya, S., Brown, E., Thomas, S. A., Taylor, N., Rothwell, J., Pope, J., Chamberlain, A., Page, E. C., Benafif, S., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106407 · Cited by 36
Diseases Predisposing to Adrenocortical Malignancy (Li–Fraumeni Syndrome, Beckwith–Wiedemann Syndrome, and Carney Complex)
Jouinot, A., & Bertherat, J. Y. (2019) · Experientia supplementum · doi:10.1007/978-3-030-25905-1_9 · Cited by 32
Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li–Fraumeni syndrome)
Petry, V., Bonadio, R. C., Cagnacci, A. Q. C., Leite, L. A. S., Campos, R., Cotti, G. C. D. C., Hoff, P. M., Fragoso, M. C. B. V., & Estevez-Diz, M. D. P. (2019) · Familial Cancer · doi:10.1007/s10689-019-00153-5 · Cited by 32
Germline cancer predisposition variants and pediatric glioma: a population-based study in California
Muskens, I. S., de Smith, A. J., Zhang, C., Hansen, H. M., Morimoto, L. M., Metayer, C., Ma, X., Walsh, K. M., & Wiemels, J. L. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa014 · Cited by 32
Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience
Pondrom, M., Bougeard, G., Karanian, M., Bonneau‐lagacherie, J., Boulanger, C., Boutroux, H., Briandet, C., Chevreau, C., Corradini, N., Coze, C., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28486 · Cited by 32
Self-citation
Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome
Formiga, M. N., de Andrade, K. C., Kowalski, L. P., & Achatz, M. I. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6389 · Cited by 31
Occurrence of Neuroblastoma among TP53 p.R337H Carriers
Seidinger, A. L., Fortes, F. P., Mastellaro, M. J., Cardinalli, I. A., Zambaldi, L. D. J. G., Aguiar, S. S., & Yunes, J. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140356 · Cited by 30
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
Petridis, C., Arora, I., Shah, V., Megalios, A., Moss, C. L., Mera, A., Clifford, A., Gillett, C., Pinder, S. E., Tomlinson, I. P. M., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1143-y · Cited by 30
Genetics of breast cancer: management strategies and risk-reducing surgery
Balasubramanian, R., Rolph, R. C., Morgan, C., & Hamed, H. (2019) · British Journal of Hospital Medicine · doi:10.12968/hmed.2019.80.12.720 · Cited by 30
BRCA1/P53: Two strengths in cancer chemoprevention
Raimundo, L., Ramos, H., Loureiro, J. B., Calheiros, J., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188339 · Cited by 30
Germline predisposition to hematopoietic malignancies
Feurstein, S. K., Drazer, M. W., & Godley, L. A. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab141 · Cited by 30
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer
Rhiem, K., Auber, B., Briest, S., Dikow, N., Ditsch, N. C., Dragicevic, N., Grill, S., Hahnen, E., Horvath, J. E., Jaeger, B. A., et al. (2021) · Breast Care · doi:10.1159/000516376 · Cited by 30
Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients
Paixão, D., Guimarães, M. D., de Andrade, K. C., de Nóbrega, A. F., Chojniak, R., & Achatz, M. I. (2018) · Cancer Imaging · doi:10.1186/s40644-018-0162-8 · Cited by 30
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
Montellier, E., Lemonnier, N., Penkert, J., Freycon, C., Blanchet, S., Amadou, A., Chuffart, F., Fischer, N. W., Achatz, M.-I., Levine, A. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111296 · Cited by 29
Self-citation
An Observed Effect of p53 Status on the Bystander Response to Radiation-Induced Cellular Photon Emission
Le, M. S., Mothersill, C. E., Seymour, C. B., Rainbow, A. J., & McNeill, F. E. (2017) · Radiation Research · doi:10.1667/rr14342.1 · Cited by 29
Genotype–phenotype associations among panel-based TP53+ subjects
Rana, H. Q., Clifford, J., Hoang, L., LaDuca, H., Black, M. H., Li, S., McGoldrick, K., Speare, V., Dolinsky, J. S., Gau, C., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0541-y · Cited by 31
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant
Deng, Q., Hu, H., Yu, X., Liu, S., Wang, L., Chen, W., Zhang, C., Zeng, Z., Cao, Y., Xu-Monette, Z. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13002-x · Cited by 32
Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li‐Fraumeni Syndrome
Peters, J. A., Kenen, R. H., Bremer, R. C., Givens, S. S., Savage, S. A., & Mai, P. L. (2015) · Journal of Genetic Counseling · doi:10.1007/s10897-015-9905-x · Cited by 33
National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract
Dhooge, M., Baert‐Desurmont, S., Corsini, C., Caron, O., Andrieu, N., Berthet, P., Bonadona, V., Cohen‐Haguenauer, O., Pauw, A. D., Delnatte, C., et al. (2020) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2020.104080 · Cited by 28
Self-citation
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31
Current insights into the regulation of programmed cell death by TP53 mutation in cancer
Su, Y., Sai, Y., Zhou, L., Liu, Z., Du, P., Wu, J., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023427 · Cited by 29
Head and neck pleomorphic myxoid liposarcoma in a child with Li-Fraumeni syndrome
Francom, C. R., Leoniak, S., Lovell, M. A., & Herrmann, B. W. (2019) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2019.05.016 · Cited by 28
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Rippinger, N., Fischer, C., Haun, M. W., Rhiem, K., Grill, S., Kiechle, M. B., Cremer, F. W., Kast, K., Nguyen, H. P., Ditsch, N. C., et al. (2020) · Cancer · doi:10.1002/cncr.33004 · Cited by 28
A new genotoxicity assay based on p53 target gene induction
Zerdoumi, Y., Kasper, E., Soubigou, F., Adriouch, S., Bougeard, G., Frébourg, T., & Flaman, J. (2015) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2015.05.010 · Cited by 28
Self-citation
Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity
Pinto, P., Paulo, P., Santos, C., Rocha, P., Pinto, C., Veiga, I., Pinheiro, M., Peixoto, A., & Teixeira, M. R. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3948-z · Cited by 27
Origin of Cancer: Cell work is the Key to Understanding Cancer Initiation and Progression
Hanselmann, R. G., & Welter, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.787995 · Cited by 31
TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling
Bittar, C. M., Vieira, I. A., Sabato, C. S., Andreis, T. F., Alemar, B., Artigalás, O., Galvão, H. D. C. R., Macedo, G. S., Palmero, E. I., & Ashton‐Prolla, P. (2019) · Familial Cancer · doi:10.1007/s10689-019-00140-w · Cited by 26
High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer
Evans, D. G., van Veen, E. M., Byers, H., Evans, S. J., Burghel, G. J., Woodward, E. R., Harkness, E. F., Eccles, D., Greville-Heygate, S. L., Ellingford, J. M., et al. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107347 · Cited by 26
Hereditary Gynecologic Cancer Syndromes – A Narrative Review
Kostov, S., Watrowski, R., Kornovski, Y., Dzhenkov, D., Slavchev, S., Ivanova, Y., & Yordanov, A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s353054 · Cited by 26
Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients
Couto, P. P., Bastos‐Rodrigues, L., Schayek, H., Melo, F. M., Cardenas, R. G. C. D. C. L., de Miranda, D. M., Vilhena, A. F., Bale, A. E., Friedman, E., & Marco, L. A. D. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx089 · Cited by 26
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer
Sheng, S., Xu, Y., Guo, Y., Yao, L., Hu, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32424 · Cited by 26
Re-envisioning genetic predisposition to childhood and adolescent cancers
Kratz, C. P. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00775-7 · Cited by 29
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum
Fortuño, C., Feng, B., Carroll, C., Innella, G., Kohlmann, W. K., Lázaro, C., Brunet, J., Feliubadaló, L., Iglesias, S. L., Menéndez, M., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00453 · Cited by 25
Risk factors for glioblastoma are shared by other brain tumor types
Smith, C. J., Perfetti, T. A., Chokshi, C., Venugopal, C., Ashford, J. W., & Singh, S. K. (2024) · Human & Experimental Toxicology · doi:10.1177/09603271241241796 · Cited by 25
Recurrent TP53 missense mutation in cancer patients of Arab descent
Zick, A., Kadouri, L., Cohen, S., Frohlinger, M., Hamburger, T., Zvi, N., Plaser, M., Eilat, A., Breuier, S., Elian, F., et al. (2016) · Familial Cancer · doi:10.1007/s10689-016-9951-z · Cited by 25
EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer
McDevitt, T., Durkie, M., Arnold, N., Burghel, G. J., Butler, S., Claes, K., Logan, P., Robinson, R., Sheils, K., Wolstenholme, N., et al. (2024) · European Journal of Human Genetics · doi:10.1038/s41431-023-01507-5 · Cited by 32
TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort
Bakhuizen, J. J., Hogervorst, F. B. L., Velthuizen, M. E., Ruijs, M., van Engelen, K., van Os, T. A. M., Gille, J. J., Collee, M. J., van den Ouweland, A. M., van Asperen, C. J., et al. (2019) · Familial Cancer · doi:10.1007/s10689-018-00118-0 · Cited by 24
Characteristics of Li‐Fraumeni syndrome in Japan: A review study by the special committee of JSHT
Funato, M., Tsunematsu, Y., Yamazaki, F., Tamura, C., Kumamoto, T., Takagi, M., Kato, S., Sugimura, H., & Tamura, K. (2021) · Cancer Science · doi:10.1111/cas.14919 · Cited by 24
Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma
Otani, S., Date, Y., Ueno, T., Ito, T., Kajikawa, S., Omori, K., Taniuchi, I., Umeda, M., Komori, T., Toguchida, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02120-w · Cited by 25
Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing
Mester, J. L., Jackson, S. A., Postula, K. J. V., Stettner, A. R., Solomon, S. R., Bissonnette, J., Murphy, P. D., Klein, R. T., & Hruska, K. S. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.12.003 · Cited by 27
Genetic predisposition to lymphomas: Overview of rare syndromes and inherited familial variants
Szmyd, B. M., Mlynarski, W. M., & Pastorczak, A. K. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108386 · Cited by 23
Hereditary Gynecologic Cancer Syndromes – A Narrative Review
Kostov, S. G., Watrowski, R., Kornovski, Y. D., Dzhenkov, D. L., Slavchev, S. H., Ivanova, Y., & Yordanov, A. D. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 23
Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome
Kolodziejczak, A. S., Guerrini‐Rousseau, L., Masliah‐Planchon, J., Ecker, J., Selt, F., Mynarek, M., Obrecht, D., Sill, M., Autry, R. J., Stutheit-Zhao, E., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad114 · Cited by 26
Self-citation
Genetic testing in a cohort of young patients with HER2-amplified breast cancer
Eccles, D., Li, N., Handwerker, R., Maishman, T., Copson, E., Durcan, L., Gerty, S., Jones, J. L., Evans, D. G., Haywood, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv592 · Cited by 23
Identification of two 14q32 deletions involving DICER1 associated with the development of DICER1-related tumors
Herriges, J. C., Brown, S., Longhurst, M. C., Ozmore, J. R., Moeschler, J. B., Janze, A., Meck, J. M., South, S. T., & Andersen, E. (2018) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2018.04.011 · Cited by 23
CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
Chen, L., Xu, B., Long, X., Gu, J., Lou, Y., Wang, D., Cao, Y., Wang, N., Li, C., Wang, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000364 · Cited by 23
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines
Fortuño, C., Mester, J. L., Pesaran, T. F., Weitzel, J. N., Dolinsky, J. S., Yussuf, A., McGoldrick, K., Garber, J. E., Savage, S. A., Khincha, P. P., et al. (2020) · Human Mutation · doi:10.1002/humu.24060 · Cited by 23
Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome
Nichols, K. E., & Malkin, D. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5757 · Cited by 27
Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders
Saida, S. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0485-x · Cited by 22
Chasing ctDNA in Patients With Sarcoma
Coombs, C. C., Dickherber, T., & Crompton, B. D. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280749 · Cited by 23
Whole-Body MRI Surveillance of Cancer Predisposition Syndromes: Current Best Practice Guidelines for Use, Performance, and Interpretation
Grasparil, A. D. I., Gottumukkala, R. V., Greer, M. C., & Gee, M. S. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.22399 · Cited by 22
A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
TP53-associated early breast cancer: new observations from a large cohort
Sandoval, R. L., Bottosso, M., Li, T., Polidorio, N., Bychkovsky, B., Verret, B., Gennari, A., Hyman, S., Achatz, M. I., Caron, O., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae074 · Cited by 23
Self-citation
Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse
Schmutzler, R. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-108531 · Cited by 21
Paired Tumor-Normal Sequencing Provides Insights Into the TP53 -Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome
Ceyhan‐Birsoy, O., Selenica, P., Chui, M. H., Jayakumaran, G., Ptashkin, R. N., Misyura, M., Aypar, U., Jairam, S., Yang, C., Li, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab117 · Cited by 22
DNMT3Aovergrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults
Ferris, M. A., Smith, A. M., Heath, S. E., Duncavage, E. J., Oberley, M. J., Freyer, D. R., Wynn, R. F., Douzgou, S., Maris, J. M., Reilly, A. F., et al. (2021) · Blood · doi:10.1182/blood.2021014052 · Cited by 21
Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome
Park, K., Choi, H.-J., Suh, S., Ki, C., & Kim, J. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.5.463 · Cited by 21
TP53 and CDKN1A mutation analysis in families with Li–Fraumeni and Li–Fraumeni like syndromes
Andrade, R. C., dos Santos, A. C. E., Neto, J. C. D. A., Nevado, J. B., Lapunzina, P. D., & Vargas, F. R. (2016) · Familial Cancer · doi:10.1007/s10689-016-9935-z · Cited by 21
Surveillance of Dutch Patients With Li-Fraumeni Syndrome
Ruijs, M., Loo, C. E., van Buchem, C. A. J. M., Bleiker, E. M. A., & Sonke, G. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1346 · Cited by 21
“I need to know if I’m going to die young”: Adolescent and young adult experiences of genetic testing for Li–Fraumeni syndrome
Shepherd, R. F., Werner‐Lin, A., Keogh, L. A., Delatycki, M. B., & Forrest, L. E. (2020) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2020.1768199 · Cited by 21
Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
Rogoża-Janiszewska, E., Malińska, K., Górski, B., Scott, R. J., Cybulski, C., Kluźniak, W., Lener, M. R., Jakubowska, A., Gronwald, J., Huzarski, T., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01151-7 · Cited by 21
TP53 Deficiency in the Natural History of Prostate Cancer
Ofner, H., Kramer, G., Shariat, S. F., & Hassler, M. R. (2025) · Cancers · doi:10.3390/cancers17040645 · Cited by 23
BRCA and Breast Cancer-Related High-Penetrance Genes
Han, S., & Kim, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_25 · Cited by 22
Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel
Byrjalsen, A., Diets, I. J., Bakhuizen, J. J., Hansen, T. V. O., Schmiegelow, K., Gerdes, A., Stoltze, U. K., Kuiper, R. P., Merks, J. H. M., Wadt, K., et al. (2021) · Familial Cancer · doi:10.1007/s10689-021-00254-0 · Cited by 20
Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists
Duployez, N., Lejeune, S., Renneville, A., & Preudhomme, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1257936 · Cited by 21
Estimating TP53 Mutation Carrier Probability in Families with Li–Fraumeni Syndrome Using LFSPRO
Peng, G., Bojadzieva, J., Ballinger, M. L., Li, J., Blackford, A. L., Mai, P. L., Savage, S. A., Thomas, D. M., Strong, L. C., & Wang, W. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0695 · Cited by 19
Parent–child communication surrounding genetic testing for Li–Fraumeni syndrome: Living under the cloud of cancer
Valdez, J. M., Walker, B. S., Ogg, S. W., Gattuso, J. S., Alderfer, M. A., Zelley, K., Ford, C. A., Baker, J. N., Mandrell, B. N., & Nichols, K. E. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27350 · Cited by 20
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity
Penkert, J., Schmidt, G., Hofmann, W. A., Schubert, S., Schieck, M., Auber, B., Ripperger, T., Hackmann, K., Sturm, M., Prokisch, H., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1011-1 · Cited by 20
TP53 , a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes
Terradas, M., Mur, P., Belhadj, S., Woodward, E. R., Burghel, G. J., Muñoz-Torres, P., Quintana, I., Navarro, M., Brunet, J., Lázaro, C., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321825 · Cited by 19
A review of inherited cancer susceptibility syndromes
Brown, G. R., Simon, M. E., Wentling, C., Spencer, D. M., Parker, A. N., & Rogers, C. A. (2020) · JAAPA · doi:10.1097/01.jaa.0000721648.46099.2c · Cited by 20
Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas
Ceglie, G., Baldo, G. D., Agolini, E., Rinelli, M., Cacchione, A., Bufalo, F. D., Vinci, M., Carta, R., Boccuto, L., Miele, E., et al. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.561487 · Cited by 21
Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours
van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G., & Fröhling, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.011 · Cited by 20
Emerging insights into ethnic-specific TP53 germline variants
Fischer, N. W., Ma, Y.-H. V., & Gariépy, J. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad106 · Cited by 24
Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy
Farncombe, K. M., Wong, D., Norman, M. L., Oldfield, L. E., Sobotka, J. A., Basik, M., Bombard, Y., Carile, V., Dawson, L. M., Foulkes, W. D., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.08.014 · Cited by 20
Fischer 344-Tp53 knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis
Hansen, S. A., Hart, M. L., Busi, S. B., Parker, T. W., Goerndt, A., Jones, K. B., Amos-Landgraf, J. M., & Bryda, E. C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025767 · Cited by 19
Breast cancer in patients with Li–Fraumeni syndrome – a case-series study and review of literature
Nandikolla, A. G., Venugopal, S., & Anampa, J. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s134241 · Cited by 19
Incidental findings from cancer next generation sequencing panels
Maani, N., Panabaker, K., McCuaig, J. M., Buckley, K., Semotiuk, K., Farncombe, K. M., Ainsworth, P., Panchal, S., Sadiković, B., Armel, S. R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00224-6 · Cited by 18
Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population
Shen, L. H., Zhang, S., Wang, K., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740227 · Cited by 21

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks